# MicroCyto

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microcyto

- Industry: Materials
- Headquarters: Beijing, China
- Website: www.microcyto.cn
- Total disclosed funding: $57M
- Latest round: Series A (Mar 30, 2026)
- Investors on record: 8

## About

Established in 2021, and based in Beijing, China, Weiyuan Synthetic Biotechnology (Beijing) Co., Ltd. , doing business named MicroCyto, operates as a biotechnology company that focuses on R&D, and production of synthetic biology products. The company has production and R&D bases in Qinhuangdao, and the founder Bo Liu graduated from the Institute of Microbiology, Chinese Academy of Science, and has nearly ten years of experience in the field of synthetic biology. As for 2023, the firm has a team which one-third of the R&D team are PhDs graduated from Chinese Academy of Sciences, Tsinghua University and other institutions, and more than 80% of them have master degrees. In March 2026, MicroCyto raised a series A+ funding from He'nan Investment Group.

The company uses low-carbon, energy-efficient and sustainable methods to produce a wide range of compounds for applications in pharmaceuticals, household chemicals, agriculture, food, feed and materials. Specific products include biologically synthesized mannitol, which is anaerobically fermented through synthetic biotechnology, and the fermented product, in addition to mannitol, can be subsequently separated and purified to yield sodium gluconate, gluconolactone or calcium gluconate.

The company utilizes synthetic biotechnology to generate revenues by developing, manufacturing, and marketing compound products with applications in pharmaceuticals, household chemicals, agriculture, food, and other fields.

The series A+ round of financing will help MicroCyto broaden the application boundaries of AI biological computing and increase investment in core technology research and development and scenario-based implementation.

## Funding rounds

- Series A, Mar 30, 2026 — He'nan Investment Group
- Series A, Aug 29, 2024, $42M — CS Capital, Shenzhen Capital Real Estate Fund, He'nan Investment Group, Shunxi Fund, Hebei Industrial Investment
- Angel, May 30, 2022, $15M — K2VC, MPC, He'nan Investment Group, BioTrack Capital

## Investors

- K2VC (https://capitalatlas.ai/funds/k2vc) — Angel
- MPC — Angel
- He'nan Investment Group (https://capitalatlas.ai/funds/he-nan-investment-group) — Angel, Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Angel
- CS Capital — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series A
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series A
- Hebei Industrial Investment — Series A